Warm Autoimmune Hemolytic Anemia Waiha clinical trials

Explore recruiting warm autoimmune hemolytic anemia waiha clinical trials.

Recruiting warm autoimmune hemolytic anemia waiha studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Warm Autoimmune Hemolytic Anemia Waiha trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Efficacy and Safety of M281 in Adults with Warm Autoimmune Hemolytic Anemia: A Multicenter, Randomized, Double blind, Placebo controlled Study with a Long-term Open-label Extension

Hungary, Czechia, France, Greece, Netherlands, Poland +3 more

Phase II and Phase III (Integrated) EU CTIS Study details

A phase 3, randomized, double-blind, study to assess efficacy and safety of ianalumab (VAY736) versus placebo in warm autoimmune hemolytic anemia (wAIHA) patients who failed at least one line of treatment (VAYHIA)

Germany, Hungary, Italy, Romania, Spain, France

Therapeutic confirmatory (Phase III) EU CTIS Study details

Exploratory Study of Ianalumab in Adults with Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) who Have Previously Benefited from Ianalumab (VAY RE-HIT)

Germany, Czechia, Belgium, Spain, Italy, Bulgaria +3 more

Therapeutic exploratory (Phase II) EU CTIS Study details

A phase 3, multicenter, randomized, double-blind, placebo- controlled, parallel-group study with an open-label period and long-term extension to assess the efficacy and safety of rilzabrutinib in participants with warm autoimmune hemolytic anemia (wAIHA)

Netherlands, Greece, Sweden, Spain, Hungary, Czechia +5 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Open-Label Study to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Povetacicept in Subjects with Autoimmune Cytopenias (RUBY-4)

Italy, Spain, Norway, Austria, Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

Warm Autoimmune Hemolytic Anemia Waiha trials by city

Warm Autoimmune Hemolytic Anemia Waiha in Toronto Warm Autoimmune Hemolytic Anemia Waiha in Vancouver Warm Autoimmune Hemolytic Anemia Waiha in Montreal Warm Autoimmune Hemolytic Anemia Waiha in Calgary Warm Autoimmune Hemolytic Anemia Waiha in Edmonton Warm Autoimmune Hemolytic Anemia Waiha in Ottawa Warm Autoimmune Hemolytic Anemia Waiha in Winnipeg Warm Autoimmune Hemolytic Anemia Waiha in Quebec City Warm Autoimmune Hemolytic Anemia Waiha in Hamilton Warm Autoimmune Hemolytic Anemia Waiha in Kitchener Warm Autoimmune Hemolytic Anemia Waiha in London Warm Autoimmune Hemolytic Anemia Waiha in Halifax Warm Autoimmune Hemolytic Anemia Waiha in New York Warm Autoimmune Hemolytic Anemia Waiha in Los Angeles Warm Autoimmune Hemolytic Anemia Waiha in Chicago Warm Autoimmune Hemolytic Anemia Waiha in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease